title: Multicenter phase II study of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric cancer.
abstract: OBJECTIVE
  Since a weekly administration of paclitaxel has demonstrated a sustained efficacy and more favorable toxicity profile than a 3-weekly administration for various solid tumors, the present study was conducted to evaluate the efficacy and safety of a combination regimen of weekly paclitaxel plus cisplatin in patients with advanced gastric cancer.
  
  
  METHODS
  Patients with previously untreated metastatic or recurrent, measurable gastric cancer received intravenous paclitaxel 100 mg/m(2) plus cisplatin 35 mg/m(2) on days 1 and 8 based on a 3-week cycle.
  
  
  RESULTS
  Fifty-two patients were enrolled in the current study. Two complete responses and 17 partial responses were confirmed, giving an overall response rate of 36.5%. At a median follow-up of 8.5 months, the median time to progression and median overall survival was 6.0 and 10.8 months, respectively. Grade 3 neutropenia occurred in ten patients, while no grade 4 neutropenia or febrile neutropenia was observed. The most common non-hematologic toxicity was nausea (grade 1/2, 56.9%). There were no treatment-related deaths.
  
  
  CONCLUSIONS
  A weekly paclitaxel and cisplatin combination was found to be well-tolerated and effective in patients with advanced gastric cancer. Accordingly, this regimen can be regarded as an important first-line treatment option for advanced gastric cancer.
authors.affiliation: Department of Oncology/Hematology, Kyungpook National University Hospital, Kyungpook National University School of Medicine, Daegu, Korea.
authors.forename: Jong Gwang
authors.initials: JG
authors.lastname: Kim
authors.forename: Sang Kyun
authors.initials: SK
authors.lastname: Sohn
authors.forename: Hong Suk
authors.initials: HS
authors.lastname: Song
authors.forename: Ki-Young
authors.initials: KY
authors.lastname: Kwon
authors.forename: Young Rok
authors.initials: YR
authors.lastname: Do
authors.forename: Kyung Hee
authors.initials: KH
authors.lastname: Lee
authors.forename: Myung Soo
authors.initials: MS
authors.lastname: Hyun
authors.forename: Hun Mo
authors.initials: HM
authors.lastname: Ryoo
authors.forename: Sung Hwa
authors.initials: SH
authors.lastname: Bae
authors.forename: Keon Uk
authors.initials: KU
authors.lastname: Park
authors.forename: Jin Ho
authors.initials: JH
authors.lastname: Baek
authors.forename: Won Sik
authors.initials: WS
authors.lastname: Lee
authors.forename: Joo Seop
authors.initials: JS
authors.lastname: Chung
authors.forename: Goon Jae
authors.initials: GJ
authors.lastname: Cho
authors.forename: Chang-Hak
authors.initials: CH
authors.lastname: Sohn
authors.forename: Jung Soon
authors.initials: JS
authors.lastname: Jang
authors.forename: Ho Young
authors.initials: HY
authors.lastname: Chung
authors.forename: Wansik
authors.initials: W
authors.lastname: Yu
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D018450:Disease Progression; D005260:Female; D005334:Fever / Q000139:chemically induced; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009362:Neoplasm Metastasis; D009503:Neutropenia / Q000139:chemically induced; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D012008:Recurrence; D013274:Stomach Neoplasms / Q000188:drug therapy*; D015996:Survival Rate
chemical_list: D017239:Paclitaxel; D002945:Cisplatin